HNB
CHRS icon

Huntington National Bank’s Coherus Oncology CHRS Stock Holding History

Huntington National Bank’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2 Hold
1
– – ﹤0.01% 4019
2025
Q4 		$1 Hold
1
– – ﹤0.01% 3981
2025
Q3 		$2 Hold
1
– – ﹤0.01% 3961
2025
Q2 		$1 Hold
1
– – ﹤0.01% 4014
2025
Q1 		$1 Hold
1
– – ﹤0.01% 4026
2024
Q4 		$1 Hold
1
– – ﹤0.01% 4021
2024
Q3 		$1 Hold
1
– – ﹤0.01% 4016
2024
Q2 		$2 Hold
1
– – ﹤0.01% 3919
2024
Q1 		$2 Hold
1
– – ﹤0.01% 3790
2023
Q4 		$3 Hold
1
– – ﹤0.01% 3660
2023
Q3 		$4 Hold
1
– – ﹤0.01% 3603
2023
Q2 		$4 Hold
1
– – ﹤0.01% 3555
2023
Q1 		$7 Hold
1
– – ﹤0.01% 3324
2022
Q4 		$8 Hold
1
– – ﹤0.01% 3153
2022
Q3 		$0 Hold
1
– – ﹤0.01% 2049
2022
Q2 		$0 Hold
1
– – ﹤0.01% 2080
2022
Q1 		$0 Hold
1
– – ﹤0.01% 2072
2021
Q4 		$0 Buy
+1
New +$17 ﹤0.01% 2044
2020
Q2 		– Sell
-274
Closed -$4K – 1518
2020
Q1 		$4K Sell
274
-815
-75% -$15.1K ﹤0.01% 1358
2019
Q4 		$20K Buy
1,089
+245
+29% +$4.52K ﹤0.01% 1244
2019
Q3 		$17K Buy
+844
New +$16.9K ﹤0.01% 1152

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Huntington National Bank's CHRS Position: Q1 2026 in Review

Huntington National Bank held its Coherus Oncology (CHRS) position steady in Q1 2026 at 1 share worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #4019.

Huntington National Bank first reported a position in CHRS in Q3 2019 and has held it in 21 quarters since. The position peaked at $20K in Q4 2019. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Huntington National Bank held 1 share of Coherus Oncology worth $2 as of Q1 2026.
  • Huntington National Bank left its Coherus Oncology share count unchanged in Q1 2026.
  • Coherus Oncology made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #4019 holding.
  • Huntington National Bank first reported a position in Coherus Oncology in Q3 2019 and has held it in 21 quarters since.
  • Huntington National Bank's Coherus Oncology position peaked at $20K in Q4 2019.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.